Overview
- The companies announced a multi‑million‑dollar co‑development agreement to build large, multimodal foundation models aimed at decoding aging biology and supporting predictive healthcare.
- Insilico will supply model architecture, benchmarking, training infrastructure and MMAI Gym tools to develop and evaluate the multimodal AI systems.
- HLFM, a new entity created by Human Longevity, will provide de‑identified genomic, proteomic, imaging and longitudinal clinical data from a decade‑long repository to train the models.
- The firms say the models are intended for future commercial use to support early detection, risk prediction and AI‑driven drug discovery, but no validation results or regulatory clearances have been published yet.
- The deal frames large commercial potential for longevity technology and raises practical questions about data privacy, model governance and clinical validation as the systems move from development toward deployment.